{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:18:05Z","timestamp":1783423085002,"version":"3.54.6"},"reference-count":61,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003718","name":"KIOM","doi-asserted-by":"crossref","award":["KSN2225011"],"award-info":[{"award-number":["KSN2225011"]}],"id":[{"id":"10.13039\/501100003718","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Despite decades of intensive research, therapeutic advances in amyotrophic lateral sclerosis (ALS) remain limited. Increasing evidence suggests that ALS is a multisystem disorder involving motor neuron degeneration, immune dysregulation, skeletal muscle pathology, and gastrointestinal dysfunction, thereby challenging the adequacy of current therapeutic strategies. Complementary and alternative medicine (CAM) approaches are widely used by patients with ALS. However, their efficacy remains controversial owing to limited clinical evidence and methodological limitations. The multicomponent herbal medicine and system-level characteristics of CAM conceptually align with the emerging view of ALS as a multisystemic disease. The involvement of gut microbiome dysbiosis in the pathophysiology of ALS has provided a unifying biological framework linking the peripheral, metabolic, and neuroinflammatory processes. These findings suggest that the combination of CAM and conventional therapy may serve as a potential integrative approach to target gut\u2013brain\u2013muscle interactions and systemic disease pathways. This article highlights critical gaps in the existing evidence and proposes that microbiome-focused, biomarker-driven clinical trials are essential to thoroughly evaluate CAM-based interventions in ALS. Embracing a system-oriented therapeutic framework may help address the complexity of ALS beyond traditional neuron-centered approaches.<\/jats:p>","DOI":"10.31083\/fbl52497","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:50:51Z","timestamp":1783421451000},"source":"Crossref","is-referenced-by-count":0,"title":["Amyotrophic Lateral Sclerosis as a Systemic Disease: Why Integrative and Microbiome-Focused Approaches Deserve Re-Evaluation"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2963-3923","authenticated-orcid":true,"given":"Eun Jin","family":"Yang","sequence":"first","affiliation":[{"name":"NeuroGlymph Imaging and Modulation Center (NIMC), Korea Institute of Oriental Medicine (KIOM), 1672 Yuseong-daero, Yuseong-gu, 34054 Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group. The New England Journal of Medicine. 1994; 330: 585\u2013591.","DOI":"10.1056\/NEJM199403033300901"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, et al. Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. The Lancet Neurology. 2017; 16: 505\u2013512. https:\/\/doi.org\/","DOI":"10.1016\/S1474-4422(17)30115-1"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nature Reviews. Disease Primers. 2017; 3: 17071.","DOI":"10.1038\/nrdp.2017.71"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016; 539: 197\u2013206.","DOI":"10.1038\/nature20413"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Loeffler JP, Picchiarelli G, Dupuis L, Gonzalez De Aguilar JL. The Role of Skeletal Muscle in Amyotrophic Lateral Sclerosis. Brain Pathology (Zurich, Switzerland). 2016; 26: 227\u2013236.","DOI":"10.1111\/bpa.12350"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019; 572: 474\u2013480.","DOI":"10.1038\/s41586-019-1443-5"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Fang X, Wang X, Yang S, Meng F, Wang X, Wei H, et al. Evaluation of the microbial diversity in amyotrophic lateral sclerosis using high-throughput sequencing. Frontiers in Microbioloy. 2016; 7: 1479.","DOI":"10.3389\/fmicb.2016.01479"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Brown RH. Al-Chalabi A. Amyotrophic lateral sclerosis. The New England Journal of Medicine. 2017; 377: 162\u2013172.","DOI":"10.1056\/NEJMra1603471"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. The Lancet. Neurology. 2019; 18: 211\u2013220.","DOI":"10.1016\/S1474-4422(18)30394-6"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Current Opinion in Neurology. 2018; 31: 635\u2013639.","DOI":"10.1097\/WCO.0000000000000599"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Dobrowolny G, Martini M, Scicchitano BM, Romanello V, Boncompagni S, Nicoletti C, et al. Muscle expression of SOD1G93A triggers the dismantlement of neuromuscular junction via PKC-theta. Antioxid Redox Signal.Cell Metabolism. 2018; 28: 1105\u20131119.","DOI":"10.1089\/ars.2017.7054"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. The Lancet. Neurology. 2011; 10: 75\u201382.","DOI":"10.1016\/S1474-4422(10)70224-6"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. The Lancet. Neurology. 2011; 10: 253\u2013263.","DOI":"10.1016\/S1474-4422(11)70015-1"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"McCombe PA, Henderson RD. The Role of immune and inflammatory mechanisms in ALS. Current Molecular Medicine. 2011; 11: 246\u2013254.","DOI":"10.2174\/156652411795243450"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science (New York, N.Y.). 2012; 336: 1262\u20131267.","DOI":"10.1126\/science.1223813"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Adams J, Lee M, Peng W. Critical review of complementary and alternative medicine use in amyotrophic lateral sclerosis: Prevalence and users' profile, decision-making, information seeking, and disclosure in the face of a lack of efficacy. Neurodegenerative Diseases. 2018; 18: 225\u2013232.","DOI":"10.1159\/000492946"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Cai M, Yang EJ. Complementary and alternative medicine for treating amyotrophic lateral sclerosis: A narrative review. Integrative Medicine Research. 2019; 8: 234\u2013239.","DOI":"10.1016\/j.imr.2019.08.003"},{"key":"ref18","unstructured":"Wang T, Yang X, Du R, Zheng S, Cui H. Acupuncture in the Treatment of Amyotrophic Lateral Sclerosis: A Research Progress in Clinical Trials. Alternative Therapies in Health and Medicine. 2023; 29: 114\u2013118."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Kim S, Mun S, Park J, Choi S, Lee S, Kim S. Complementary and alternative medicine use in amyotrophic lateral sclerosis cases in South Korea. Evidence-based Complementary and Alternative Medicine. 2019; 2019: 4217057.","DOI":"10.1155\/2019\/4217057"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Song Y, Jia Q, Guan X, Kazuo S, Liu J, Duan W, et al. Herbal medicine for amyotrophic lateral sclerosis: A systematic review and meta-analysis. Frontiers in Pharmacology. 2022; 13: 946548.","DOI":"10.3389\/fphar.2022.946548"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Suh WJ, Seo Y, Jin C, Cho SY, Park SU, Jung WS, et al. Traditional East Asian herbal medicine for amyotrophic lateral sclerosis: A scoping review. Evidence-based Complementary and Alternative Medicine. 2021; 2021: 5674142.","DOI":"10.1155\/2021\/5674142"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Brenner D, Hiergeist A, Adis C, Mayer B, Gessner A, Ludolph AC, et al. The fecal microbiome of ALS patients. Neurobiology of Aging. 2018; 61: 132\u2013137.","DOI":"10.1016\/j.neurobiolaging.2017.09.023"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Di Gioia D, Bozzi Cionci N, Baffoni L, Amoruso A, Pane M, Mogna L, et al. A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis. BMC Medicine. 2020; 18: 153.","DOI":"10.1186\/s12916-020-01607-9"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Rowin J, Xia Y, Jung B, Sun J. Gut inflammation and dysbiosis in human motor neuron disease. Physiological Reports. 2017; 5: e13443.","DOI":"10.14814\/phy2.13443"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Sun J, Huang T, Debelius JW, Fang F. Gut microbiome and amyotrophic lateral sclerosis: a systematic review of current evidence. Journal of Internal Medicine. 2021; 290: 758\u2013788.","DOI":"10.1111\/joim.13336"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Fontdevila L, Povedano M, Dom\u00ednguez R, Boada J, Serrano JC, Pamplona R, et al. Examining the complex Interplay between gut microbiota abundance and short-chain fatty acid production in amyotrophic lateral sclerosis patients shortly after onset of disease. Scientific Reports. 2024; 14: 23497.","DOI":"10.1038\/s41598-024-75083-z"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Shaw C, Hess M, Weimer BC. Microbial-Derived Tryptophan Metabolites and Their Role in Neurological Disease: Anthranilic Acid and Anthranilic Acid Derivatives. Microorganisms. 2023; 11: 1825.","DOI":"10.3390\/microorganisms11071825"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Niccolai E, Di Pilato V, Nannini G, Baldi S, Russo E, Zucchi E, et al. The gut microbiota\u2013immunity axis in ALS: A role in deciphering disease heterogeneity?. Biomedicines. 2021; 9: 753.","DOI":"10.3390\/biomedicines9070753"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Hertzberg VS, Singh H, Fournier CN, Moustafa A, Polak M, Kuelbs CA, et al. Gut microbiome differences between amyotrophic lateral sclerosis patients and spouse controls. Amylotrophic Lateral Sclerosis Frontotemporal Degeneration. 2022; 23: 91\u201399.","DOI":"10.1080\/21678421.2021.1904994"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Gong X, Li X, Bo A, Shi RY, Li QY, Lei LJ, et al. The interactions between gut microbiota and bioactive ingredients of traditional Chinese medicines: A review. Pharmacological Research. 2020; 157: 104824.","DOI":"10.1016\/j.phrs.2020.104824"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Wang J, Zhu N, Su X, Gao Y, Yang R. Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis. Cells. 2023; 12: 793.","DOI":"10.3390\/cells12050793"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Verosky BG, Bailey MT, Gur TL. The Metabolomic Mind: Microbial Metabolite Programming of Microglia. Neuroimmunomodulation. 2025; 32: 139\u2013149.","DOI":"10.1159\/000545484"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Wang L, Gou X, Ding Y, Liu J, Wang Y, Wang Y, et al. The interplay between herbal medicines and gut microbiota in metabolic diseases. Frontiers in Pharmacology. 2023; 14: 1105405.","DOI":"10.3389\/fphar.2023.1105405"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Li X, Liu Y, Liu N, Wu H, Cong K, Duan L, et al. Health benefits of medicinal plant natural products via microbiota-mediated different gut axes. Pharmacological Research. 2025; 215: 107730.","DOI":"10.1016\/j.phrs.2025.107730"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Chen Y, Lei Z, Gu D, Zhao H, Yu R, He Q, et al. Gut microbiota: A potential enhancing factor for the therapeutic efficacy of bioactive compounds in herbal medicines. Fitoterapia. 2025; 183: 106570.","DOI":"10.1016\/j.fitote.2025.106570"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Lin L, Luo L, Zhong M, Xie T, Liu Y, Li H, et al. Gut microbiota: a new angle for traditional herbal medicine research. RSC Advances. 2019; 9: 17457\u201317472.","DOI":"10.1039\/c9ra01838g"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Shi Y, Hu J, Geng J, Hu T, Wang B, Yan W, et al. Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE\u2212\/\u2212 mice. Biomedical & Pharmacotherapy. 2018; 107: 1556\u20131563.","DOI":"10.1016\/j.biopha.2018.08.148"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Cheng H, Liu J, Zhang D, Wang J, Tan Y, Feng W, et al. Ginsenoside Rg1 alleviates acute ulcerative colitis by modulating gut microbiota and microbial tryptophan metabolism. Frontiers in Immunology. 2022; 13: 817600.","DOI":"10.3389\/fimmu.2022.817600"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Fan Q, Guan X, Hou Y, Liu Y, Wei W, Cai X, et al. Paeoniflorin modulates gut microbial production of indole-3-lactate and epithelial autophagy to alleviate colitis in mice. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 2020; 79: 153345.","DOI":"10.1016\/j.phymed.2020.153345"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Zhang X, Jia L, Ma Q, Zhang X, Chen M, Liu F, et al. Astragalus Polysaccharide Modulates the Gut Microbiota and Metabolites of Patients with Type 2 Diabetes in an In Vitro Fermentation Model. Nutrients. 2024; 16: 1698.","DOI":"10.3390\/nu16111698"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Ba T, Niu R, Gao J, Li W, Dong M, Duan J, et al. Microbiota-gut-brain-axis: a new target of acupuncture therapy for post-stroke cognitive impairment. Frontiers in Microbiology. 2025; 16: 1425054.","DOI":"10.3389\/fmicb.2025.1425054"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Xu H, Luo Y, Li Q, Zhu H. Acupuncture influences multiple diseases by regulating gut microbiota. Frontiers in Cellular and Infection Microbiology. 2024; 14: 1371543.","DOI":"10.3389\/fcimb.2024.1371543"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Zhang Y, Ding N, Hao X, Zhao J, Zhao Y, Li Y, et al. Manual acupuncture benignly regulates blood-brain barrier disruption and reduces lipopolysaccharide loading and systemic inflammation, possibly by adjusting the gut microbiota. Frontiers in Aging Neuroscience. 2022; 14: 1018371.","DOI":"10.3389\/fnagi.2022.1018371"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Chen D, Yang X, Jiao D, Chen X, Xiao W, Zheng J, et al. Electroacupuncture ameliorates Autism Spectrum Disorder via modulating the gut-brain axis depending on the integrity of vagus nerve. Translational Psychiatry. 2025; 15: 428.","DOI":"10.1038\/s41398-025-03637-4"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Duvallet C, Gibbons SM, Gurry T, Irizarry RA, Alm EJ. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. Nature Communications. 2017; 8: 1784.","DOI":"10.1038\/s41467-017-01973-8"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Forry SP, Servetas SL, Kralj JG, Soh K, Hadjithomas M, Cano R, et al. Variability and bias in microbiome metagenomic sequencing: an interlaboratory study comparing experimental protocols. Scientific Reports. 2024; 14: 9785.","DOI":"10.1038\/s41598-024-57981-4"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Gautam P, Vishwakarma RK, Nath M, Nath G, Pathak A. Microbiota Dysbiosis in Amyotrophic Lateral Sclerosis: A Systematic Review of Human Studies. Molecular Neurobiology. 2025; 63: 10.","DOI":"10.1007\/s12035-025-05481-5"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Shin S, Chen S, Xie K, Duhun SA, Ortiz-Cerda T. Evaluating the anti-inflammatory and antioxidant efficacy of complementary and alternative medicines (CAM) used for management of inflammatory bowel disease: a comprehensive review. Redox Report : Communications in Free Radical Research. 2025; 30: 2471737.","DOI":"10.1080\/13510002.2025.2471737"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Mudda NS, Zhang L, Sampelli P. Targeting gut-brain-immune axis in amyotrophic lateral sclerosis. Frontiers in Immunology. 2026; 16: 1637976.","DOI":"10.3389\/fimmu.2025.1637976"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Ayala V, Fontdevila L, Rico-Rios S, Povedano M, Andres-Benito P, Torres P, et al. Microbial influences on amyotrophic lateral sclerosis: The gut\u2013brain axis and therapeutic potential of microbiota modulation. Sclerosis. 2025; 3: 8.","DOI":"10.3390\/sclerosis3010008"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Kaul M, Mukherjee D, Weiner HL, Cox LM. Gut microbiota immune cross-talk in amyotrophic lateral sclerosis. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics. 2024; 21: e00469.","DOI":"10.1016\/j.neurot.2024.e00469"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Chen C, Wang GQ, Li DD, Zhang F. Microbiota-gut-brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets. Molecular Biomedicine. 2025; 6: 64.","DOI":"10.1186\/s43556-025-00307-1"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Kim CS. Roles of Diet-Associated Gut Microbial Metabolites on Brain Health: Cell-to-Cell Interactions between Gut Bacteria and the Central Nervous System. Advances in Nutrition (Bethesda, Md.). 2024; 15: 100136.","DOI":"10.1016\/j.advnut.2023.10.008"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Swer NM, Venkidesh BS, Murali TS, Mumbrekar KD. Gut microbiota-derived metabolites and their importance in neurological disorders. Molecular Biology Reports. 2023; 50: 1663\u20131675.","DOI":"10.1007\/s11033-022-08038-0"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Saponaro F, Bertolini A, Baragatti R, Galfo L, Chiellini G, Saba A, et al. Myokines and Microbiota: New Perspectives in the Endocrine Muscle-Gut Axis. Nutrients. 2024; 16: 4032.","DOI":"10.3390\/nu16234032"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Xu Y, He B. The gut-muscle axis: a comprehensive review of the interplay between physical activity and gut microbiota in the prevention and treatment of muscle wasting disorders. Frontiers in Microbiology. 2025; 16: 1695448.","DOI":"10.3389\/fmicb.2025.1695448"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Zang Z, Yang F, Qu L, Ge M, Tong L, Xue L, et al. Acupuncture modulates the microbiota-gut-brain axis: a new strategy for Parkinson's disease treatment. Frontiers in Aging Neuroscience. 2025; 17: 1640389.","DOI":"10.3389\/fnagi.2025.1640389"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Kiecka A, Szczepanik M. Dietary modulation of the gut microbiome as a supportive strategy in the treatment of amyotrophic lateral sclerosis - a narrative review. Pharmacological Reports : PR. 2025; 77: 1514\u20131526.","DOI":"10.1007\/s43440-025-00800-y"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Cuffaro F, Lamminp\u00e4\u00e4 I, Niccolai E, Amedei A. Nutritional and Microbiota-Based Approaches in Amyotrophic Lateral Sclerosis: From Prevention to Treatment. Nutrients. 2024; 17: 102.","DOI":"10.3390\/nu17010102"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Feng R, Zhu Q, Wang A, Wang H, Wang J, Chen P, et al. Effect of fecal microbiota transplantation on patients with sporadic amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. BMC Medicine. 2024; 22: 566.","DOI":"10.1186\/s12916-024-03781-6"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Chui ZSW, Chan LML, Zhang EWH, Liang S, Choi EPH, Lok KYW, et al. Effects of microbiome-based interventions on neurodegenerative diseases: a systematic review and meta-analysis. Scientific Reports. 2024; 14: 9558.","DOI":"10.1038\/s41598-024-59250-w"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/6\/10.31083\/FBL52497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:52:58Z","timestamp":1783421578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/6\/10.31083\/FBL52497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02146-5"],"URL":"https:\/\/doi.org\/10.31083\/fbl52497","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"52497"}}